Ceftazidime: Difference between revisions
imported>Howard C. Berkowitz No edit summary |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
{{subpages}} | {{subpages}} | ||
'''Ceftazidime''' is a third-generation [[cephalosporin]] antibiotic with bactericidal activity | '''Ceftazidime''' is a third-generation [[cephalosporin]] antibiotic with bactericidal activity, especially against ''[[Pseudomonas aeruginosa]]''. The U.S. proprietary name is '''Fortaz'''. Indications approved by the U.S. [[Food and Drug Administration]] include: infections with [[Pseudomonas aeruginosa]], [[Escherichia coli]], [[Proteus]] species, [[Hemophilus]] species, [[Serratia]], [[Klebsiella pneumoniae]], [[Enterobacter]], [[Staphylococcus aureus]], and [[Streptococcus]]. | ||
Compared to the second and first generation cephalosporins, itis more active against [[Gram stain|gram-negative]] bacteria and less active against gram-positive bacteria. Ceftazidine also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).<ref>{{citation | Compared to the second and first generation cephalosporins, itis more active against [[Gram stain|gram-negative]] bacteria and less active against gram-positive bacteria. Ceftazidine also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).<ref>{{citation | ||
Latest revision as of 21:11, 21 August 2010
Ceftazidime is a third-generation cephalosporin antibiotic with bactericidal activity, especially against Pseudomonas aeruginosa. The U.S. proprietary name is Fortaz. Indications approved by the U.S. Food and Drug Administration include: infections with Pseudomonas aeruginosa, Escherichia coli, Proteus species, Hemophilus species, Serratia, Klebsiella pneumoniae, Enterobacter, Staphylococcus aureus, and Streptococcus.
Compared to the second and first generation cephalosporins, itis more active against gram-negative bacteria and less active against gram-positive bacteria. Ceftazidine also crosses the blood-brain barrier and reaches therapeutic concentrations in the central nervous system (CNS).[1]
Mechanism of action
It inactivates penicillin-binding proteins (PBP) located on the inner membrane of the bacterial cell wall, proteins that participate in the terminal stages of assembling the bacterial cell wall, and in reshaping the cell wall during cell division. Their inactivation interferes with the cross-linkage of peptidoglycan chains necessary for bacterial cell wall strength and rigidity, leading to cell lysis.
Risks
In one study, the use of ceftazidime was the greatest risk factor for nosocomial Acinetobacter infection.:[2]
References
- ↑ Third Generation Antipseudomonal Cephalosporins, Family Practice Notebook
- ↑ Husni RN et al (May 1999), "Risk Factors for an Outbreak of Multi-Drug-Resistant Acinetobacter Nosocomial Pneumonia Among Intubated Patients*", Chest